Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM185PE | TNBC | Luminal | Temsirolimus | MTOR | MTOR | 0.213 | uM | 12269.144 | 0.7377 | 0.4860 | 1.0241 | |
| SUM185PE | TNBC | Luminal | Temsirolimus | MTOR | MTOR | 1.07 | uM | 12269.144 | 0.6910 | 0.3941 | 1.0241 | |
| SUM185PE | TNBC | Luminal | Temsirolimus | MTOR | MTOR | 5.33 | uM | 12269.144 | 0.5030 | 0.0224 | 1.0241 | |
| SUM185PE | TNBC | Luminal | Temsirolimus | MTOR | MTOR | 26.7 | uM | 12269.144 | 0.1497 | -0.6870 | 1.0241 | |
| SUM185PE | TNBC | Luminal | Temsirolimus | MTOR | MTOR | 133 | uM | 12269.144 | 0.0133 | -0.9706 | 1.0241 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 10579.144 | 0.6807 | 0.3384 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 10579.144 | 0.6808 | 0.3387 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 10579.144 | 0.6006 | 0.1743 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 10579.144 | 0.6643 | 0.3048 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.213 | uM | 10579.144 | 0.6753 | 0.3274 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 1.07 | uM | 10579.144 | 0.6224 | 0.2190 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 5.33 | uM | 10579.144 | 0.6258 | 0.2260 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 26.7 | uM | 10579.144 | 0.3220 | -0.3874 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 10579.144 | 0.0083 | -0.9866 | 0.9576 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 12098.144 | 0.9535 | 0.9219 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 12098.144 | 0.9226 | 0.8697 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.00853 | uM | 12098.144 | 0.7541 | 0.5796 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.0427 | uM | 12098.144 | 0.6062 | 0.3159 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 0.213 | uM | 12098.144 | 0.5817 | 0.2713 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 1.07 | uM | 12098.144 | 0.5367 | 0.1885 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 5.33 | uM | 12098.144 | 0.5276 | 0.1717 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 26.7 | uM | 12098.144 | 0.2036 | -0.4716 | 1.1959 | |
| SUM225CWN | HER2amp | Basal A | Temsirolimus | MTOR | MTOR | 133 | uM | 12098.144 | 0.0088 | -0.9617 | 1.1959 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 0.000341 | uM | 11058.144 | 0.9732 | 0.9745 | 2.1171 | |
| SUM229PE | TNBC | - | Temsirolimus | MTOR | MTOR | 0.00171 | uM | 11058.144 | 1.0298 | 1.0279 | 2.1171 |